OncoMatch/Clinical Trials/NCT07011719
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Is NCT07011719 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Casdatifan and Cabozantinib for metastatic clear cell renal cell carcinoma.
Treatment: Casdatifan · Cabozantinib — The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib in adult patients with confirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experienced progression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Prior therapy
Cannot have received: HIF-2α inhibitor
Received prior treatment with a HIF-2α inhibitor
Cannot have received: MET inhibitor (cabozantinib)
Received prior treatment with...cabozantinib
Lab requirements
Blood counts
adequate organ and marrow function, ≤ 72 hours prior to randomization
Kidney function
adequate organ and marrow function, ≤ 72 hours prior to randomization
Liver function
adequate organ and marrow function, ≤ 72 hours prior to randomization
Adequate organ and marrow function, ≤ 72 hours prior to randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope - Phoenix Cancer Center · Goodyear, Arizona
- City Of Hope National Medical Center · Duarte, California
- University of California San Diego Moores Cancer Center · La Jolla, California
- UCLA Hematology Oncology - 100 Med Plaza · Los Angeles, California
- University of California San Diego Moores Cancer Center · San Diego, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify